AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23243282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg per day with dexamethasone 40 mg per week
Number of subjects: 38
Study 23243282 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg per day
Number of subjects: 38
Study 23243282 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 40 mg per week
Number of subjects: 38
Study 23243299 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F(-)/(18)F-FDG PET/CT
Number of subjects: 115
Study 23243299 — intervention group
Group type: EXPERIMENTAL
Intervention: (18)F(-) PET/CT and (18)F(-)/(18)F-FDG PET/CT
Number of subjects: 115
Study 23243299 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 scans
Number of subjects: 115
Study 23243299 — intervention group
Group type: COMPARATOR
Intervention: Combined (18)F(-)/(18)F-FDG PET/CT
Number of subjects: 115
Study 23245194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal elastase measurement
Number of subjects: 82
Study 23245284 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformal or intensity modulated radiation therapy
Number of subjects: 139
Study 23245496 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report measures of cognitive functioning
Number of subjects: 81
Study 23245496 — intervention group
Group type: EXPERIMENTAL
Intervention: History of major depressive disorder
Number of subjects: 81
Study 23245683 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture in 20% O2 (group 1)
Number of subjects: 0
Study 23245683 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture in 5% O2 (group 3)
Number of subjects: 0
Study 23245683 — intervention group
Group type: COMPARATOR
Intervention: Culture in 5% + 20% O2 (group 2)
Number of subjects: 0
Study 23246630 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcallosal cingulate white matter deep brain stimulation
Number of subjects: 0
Study 23246630 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical management in initial and long-term phases
Number of subjects: 0
Study 23247661 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOEP-14 followed by high-dose cytarabine and high-dose methotrexate
Number of subjects: 156
Study 23248254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 120 mg/m² as a 30-minute infusion on days 1 and 2 every 28 days with growth factor support
Number of subjects: 36
Study 23248254 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine
Number of subjects: 36
Study 23248257 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (2 mg orally once daily) in cohort A
Number of subjects: 97
Study 23248257 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (2 mg orally once daily) in cohort B
Number of subjects: 97
Study 23249699 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (T4) treatment
Number of subjects: 28
Study 23249699 — intervention group
Group type: COMPARATOR
Intervention: Exogenous Triiodothyronine (T3)
Number of subjects: 28
Study 23249699 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study 23250892 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml kg(-1) colloid for 10 min
Number of subjects: 33
Study 23250892 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI and ΔVpeak
Number of subjects: 33
Study 23250963 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF Tap Test (CSF TT)
Number of subjects: 115
Study 23250963 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance to CSF outflow (Rout)
Number of subjects: 115
Study 23250963 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CSF TT and Rout
Number of subjects: 115
Study 23250963 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait task (10 m walking at free speed) from CSF TT
Number of subjects: 115
Study 23250981 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent reduction in NT-proBNP
Number of subjects: 0
Study 23250981 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 23250981 — intervention group
Group type: EXPERIMENTAL
Intervention: Net fluid loss
Number of subjects: 0
Study 23250981 — intervention group
Group type: EXPERIMENTAL
Intervention: Markers of decongestion (0, 1, 2, and 3 markers above the median)
Number of subjects: 0
Study 23251403 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental tertiles of triglyceride-to-HDL cholesterol ratio
Number of subjects: 729
Study 23251403 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride-to-HDL cholesterol ratio
Number of subjects: 729
Study 23251869 — intervention group
Group type: COMPARATOR
Intervention: Later-onset TTM (≥ 12 years old)
Number of subjects: 98
Study 23251869 — intervention group
Group type: COMPARATOR
Intervention: Childhood-onset TTM (≤ 11 years old)
Number of subjects: 98
Study 23251870 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg
Number of subjects: 45
Study 23251870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 23253265 — intervention group
Group type: EXPERIMENTAL
Intervention: Marathon running
Number of subjects: 10
Study 23253405 — intervention group
Group type: EXPERIMENTAL
Intervention: Supralimus-Core® stent
Number of subjects: 105
Study 23253623 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-machine interface training with a high-performance prosthetic limb for 13 weeks.
Number of subjects: 1
Study 23253635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol
Number of subjects: 155761
Study 23253635 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 155761
Study 23253635 — intervention group
Group type: COMPARATOR
Intervention: Tapentadol vs Oxycodone
Number of subjects: 155761
Study 23253648 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a TV in the bedroom
Number of subjects: 369
Study 23253648 — intervention group
Group type: EXPERIMENTAL
Intervention: TV viewing time
Number of subjects: 369
Study 23254596 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan (AML/OM) 5/20 mg for 4 weeks, followed by uptitration to AML/OM 5/40 mg, AML/OM 10/40 mg, AML/OM 10/40 mg + HCTZ 12.5 mg, and AML/OM 10/40 mg + HCTZ 25 mg at 4-week intervals if BP remained uncontrolled.
Number of subjects: 0
Study 23255277 — intervention group
Group type: EXPERIMENTAL
Intervention: pLVAD support during ablation
Number of subjects: 20
Study 23255277 — intervention group
Group type: EXPERIMENTAL
Intervention: pLVAD support during fast simulated VT (300 ms)
Number of subjects: 20
Study 23255310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at maximum tolerated dose (MTD, 24.4 ± 4.5 mg/kg/day, range 15.3-30.6 mg/kg/day)
Number of subjects: 23
Study 23255310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea at MTD
Number of subjects: 23
Study 23256140 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy/whey ready-to-use supplementary food (RUSF)
Number of subjects: 1967
Study 23256140 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend plus milk and oil (CSB++)
Number of subjects: 1967
Study 23256140 — intervention group
Group type: COMPARATOR
Intervention: Soy ready-to-use supplementary food (RUSF)
Number of subjects: 1967
Study 23256542 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-allyamino-17-demethoxygeldanamycin (17-AAG) 150 mg/m(2) and bortezomib 0.7 mg/m(2)
Number of subjects: 11
Study 23256542 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-allyamino-17-demethoxygeldanamycin (17-AAG) in combination with bortezomib
Number of subjects: 11
Study 23256542 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 17-AAG and bortezomib
Number of subjects: 11
Study 23258777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia-altitude simulation testing (HAST)
Number of subjects: 82
Study 23258777 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen during air travel
Number of subjects: 82
Study 23259649 — intervention group
Group type: EXPERIMENTAL
Intervention: 1x10^6 adoptively transferred FAP-specific re-directed T cells injected directly in the pleural effusion.
Number of subjects: 0
Study 23259667 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m², 3qw, 6 courses)
Number of subjects: 1121
Study 23259667 — intervention group
Group type: EXPERIMENTAL
Intervention: DTC-status at BM2
Number of subjects: 1121
Study 23259667 — intervention group
Group type: EXPERIMENTAL
Intervention: DTC-status at BM1 and BM2
Number of subjects: 1121
Study 23259667 — intervention group
Group type: EXPERIMENTAL
Intervention: DTC-status before and after docetaxel treatment
Number of subjects: 1121
Study 23260081 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved unmatched allogeneic mesenchymal stromal cells (MSCs)
Number of subjects: 0
Study 23260081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23260600 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 15 mg/m² over 3 hours every 8 hours for 3 days every 6 weeks (n = 74)
Number of subjects: 163
Study 23260600 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 20 mg/m² over 1 hour daily for 5 days every 4 weeks (n = 89)
Number of subjects: 163
Study 23260600 — intervention group
Group type: EXPERIMENTAL
Intervention: Study effect (decitabine treatment)
Number of subjects: 163
Study 23261356 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (50 mg twice daily, orally) until progression
Number of subjects: 52
Study 23261356 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 52
Study 23264589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral vector–modified autologous CD4 T cells (VRX496-T)
Number of subjects: 17
Study 23265285 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol sulfate hydrofluoroalkane (HFA) metered-dose inhaler with integrated dose counter, 90 micrograms, twice-daily dosing for 5 or 7 weeks
Number of subjects: 0
Study 23265339 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular autonomic neuropathy (CAN) assessed by cardiovascular reflex testing (R-R response to paced breathing, Valsalva ratio, and blood pressure response to standing)
Number of subjects: 966
Study 23265339 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal R-R variation
Number of subjects: 966
Study 23265339 — intervention group
Group type: COMPARATOR
Intervention: Normal tests (R-R variation, Valsalva ratio, and postural blood pressure changes)
Number of subjects: 966
Study 23265711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy
Number of subjects: 1075
Study 23265712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bevacizumab (5mg/kg every 14 days) and oral rapamycin (1-6 mg/day)
Number of subjects: 24
Study 23266597 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation of atrial fibrillation
Number of subjects: 50
Study 23266597 — intervention group
Group type: COMPARATOR
Intervention: Symptoms alone
Number of subjects: 50
Study 23266597 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic episodes
Number of subjects: 50
Study 23266597 — intervention group
Group type: EXPERIMENTAL
Intervention: Postablation state
Number of subjects: 50
Study 23267529 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth problem-solving therapy (PST)
Number of subjects: 121
Study 23267529 — intervention group
Group type: COMPARATOR
Intervention: Baseline ED visit frequency
Number of subjects: 121
Study 23269537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day on a continuous daily dosing (CDD) schedule
Number of subjects: 12
Study 23269818 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARGC1A rs8192678 risk A allele
Number of subjects: 781
Study 23269818 — intervention group
Group type: COMPARATOR
Intervention: PNPLA3 rs738409
Number of subjects: 781
Study 23269861 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg (single oral dose)
Number of subjects: 34
Study 23269986 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy
Number of subjects: 140
Study 23269986 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 140
Study 23270003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and rituximab
Number of subjects: 59
Study 23270422 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-setting intervention
Number of subjects: 0
Study 23270422 — intervention group
Group type: COMPARATOR
Intervention: Education group (control)
Number of subjects: 0
Study 23270487 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglustat 100 mg t.i.d.
Number of subjects: 42
Study 23270493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 600 mg orally days -1 to +2
Number of subjects: 24
Study 23271553 — intervention group
Group type: EXPERIMENTAL
Intervention: Boomerang nerve flap
Number of subjects: 17
Study 23271553 — intervention group
Group type: COMPARATOR
Intervention: Cross-finger flap and secondary free nerve graft (Control)
Number of subjects: 17
Study 23272643 — intervention group
Group type: EXPERIMENTAL
Intervention: Diammine silver fluoride (DSF) applied to 3 teeth, mean amount 7.57 mg (6.04 μL)
Number of subjects: 6
Study 23272643 — intervention group
Group type: EXPERIMENTAL
Intervention: Diammine silver fluoride (DSF)
Number of subjects: 6
Study 23273522 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg/day and bevacizumab 15 mg/kg every 3 weeks until progression
Number of subjects: 50
Study 23273522 — intervention group
Group type: EXPERIMENTAL
Intervention: VeriStrat® analysis (Good vs Poor)
Number of subjects: 50
Study 23273726 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD status
Number of subjects: 68
Study 23273726 — intervention group
Group type: EXPERIMENTAL
Intervention: 3'-UTR of SLC6A3 9 repeat carrier status
Number of subjects: 68
Study 23273726 — intervention group
Group type: EXPERIMENTAL
Intervention: 3'-UTR genotype
Number of subjects: 68
Study 23273726 — intervention group
Group type: EXPERIMENTAL
Intervention: 3'-UTR but not intron8 VNTR genotypes
Number of subjects: 68
Study 23273726 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD status and 3'-UTR polymorphism status
Number of subjects: 68
Study 23274104 — intervention group
Group type: EXPERIMENTAL
Intervention: Kellgren & Lawrence (KL) gradings
Number of subjects: 192
Study 23274104 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Leeds Osteoarthritis Knee Score (BLOKS)
Number of subjects: 192
Study 23274104 — intervention group
Group type: EXPERIMENTAL
Intervention: BLOKS in medial tibiofemoral compartment
Number of subjects: 192
Study 23274104 — intervention group
Group type: EXPERIMENTAL
Intervention: mJSW measurements
Number of subjects: 192
Study 23274395 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal-encapsulated docetaxel (LE-DT) at 132 mg/m(2)
Number of subjects: 24
Study 23274395 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal-encapsulated docetaxel (LE-DT) at 110 mg/m(2)
Number of subjects: 24
Study 23274395 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal-encapsulated docetaxel (LE-DT) at 85 mg/m(2)
Number of subjects: 24
Study 23274395 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal-encapsulated docetaxel (LE-DT)
Number of subjects: 24
Study 23274783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure Variation (PPV)
Number of subjects: 44
Study 23274783 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrected Flow Time (FTc)
Number of subjects: 44
Study 23274889 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with β-cell autoimmunity
Number of subjects: 18
Study 23274889 — intervention group
Group type: COMPARATOR
Intervention: Autoantibody-negative children
Number of subjects: 18
Study 23274902 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant antibody increase (DSA or autoantibodies)
Number of subjects: 59
Study 23274902 — intervention group
Group type: COMPARATOR
Intervention: No posttransplant antibody increase
Number of subjects: 59
Study 23274902 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant DSA or autoantibody increases
Number of subjects: 59
Study 23274902 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapamycin
Number of subjects: 59
Study 23274906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of [6,6-²H₂]-glucose followed by ingestion of four eggs containing 23 g of labeled proteins
Number of subjects: 8
Study 23275061 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2801653
Number of subjects: 0
Study 23275350 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigator (Abbott Diabetes Care)
Number of subjects: 6
Study 23275350 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven Plus (DexCom)
Number of subjects: 6
Study 23275350 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardian (Medtronic)
Number of subjects: 6
Study 23275526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactating African-American women
Number of subjects: 60
Study 23275526 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle feeding African-American women
Number of subjects: 60
Study 23275526 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (African-American)
Number of subjects: 60
Study 23275526 — intervention group
Group type: COMPARATOR
Intervention: Caucasian women (historic comparison)
Number of subjects: 60
Study 23275610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomized subjects
Number of subjects: 20
Study 23275610 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 23276300 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe sex counseling from a primary care physician
Number of subjects: 275
Study 23276300 — intervention group
Group type: EXPERIMENTAL
Intervention: Practicing safer sex because of counseling
Number of subjects: 275
Study 23276300 — intervention group
Group type: EXPERIMENTAL
Intervention: Race/Ethnicity (Black)
Number of subjects: 275
Study 23276300 — intervention group
Group type: EXPERIMENTAL
Intervention: Manic episodes
Number of subjects: 275
Study 23276300 — intervention group
Group type: COMPARATOR
Intervention: Race/Ethnicity and mental illness indicators
Number of subjects: 275
Study 23276808 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-associated HIV polymorphisms
Number of subjects: 800
Study 23276808 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV epitopes with polymorphisms
Number of subjects: 800
Study 23276808 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV escape mechanisms
Number of subjects: 800
Study 23277518 — intervention group
Group type: EXPERIMENTAL
Intervention: Volatile organic compounds (VOCs) in exhaled breath
Number of subjects: 252
Study 23277896 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV rapid testing and audio computer-assisted self-interviews at baseline and every 6 months for up to 12 months.
Number of subjects: 2099
Study 23278639 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) 18 μg/kg/day (days 1, 2) with CHOP (day 3) every 21 days for ≤ 6-8 cycles
Number of subjects: 49
Study 23278639 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (DD) plus CHOP
Number of subjects: 49
Study 23279046 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 328
Study 23279046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild contralateral venous ectasia
Number of subjects: 328
Study 23279046 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor International Normalized Ratio (INR) control
Number of subjects: 328
Study 23279046 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual venous obstruction on ultrasound
Number of subjects: 328
Study 23279046 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (in subgroup of 244 patients without signs of contralateral venous insufficiency)
Number of subjects: 328
Study 23279046 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor INR control (in subgroup of 244 patients)
Number of subjects: 328
Study 23279046 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual venous obstruction (in subgroup of 244 patients)
Number of subjects: 328
Study 23279103 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 0
Study 23279103 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily
Number of subjects: 0
Study 23281243 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 211
Study 23281243 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 211
Study 23281844 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 78
Study 23281844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 23281876 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR 300-800 mg once daily
Number of subjects: 0
Study 23281876 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR for switches due to insufficient efficacy
Number of subjects: 0
Study 23281876 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR for switches due to insufficient tolerability
Number of subjects: 0
Study 23281876 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR for switches due to non-acceptability
Number of subjects: 0
Study 23281876 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR for patients previously on olanzapine
Number of subjects: 0
Study 23281876 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR for patients previously on quetiapine IR
Number of subjects: 0
Study 23281876 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 0
Study 23281975 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r (250 mg ABT-450 + 100 mg ritonavir) + ABT-333 (400 mg twice daily) + ribavirin (1000 to 1200 mg per day)
Number of subjects: 50
Study 23281975 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450/r (150 mg ABT-450 + 100 mg ritonavir) + ABT-333 (400 mg twice daily) + ribavirin (1000 to 1200 mg per day)
Number of subjects: 50
Study 23283106 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided focused ultrasound (MRgFUS) surgery
Number of subjects: 0
Study 23283106 — intervention group
Group type: COMPARATOR
Intervention: Standard curative whole gland therapy
Number of subjects: 0
Study 23283106 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 0
Study 23283362 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (NO synthase inhibitor)
Number of subjects: 23